Compare Stocks: CLYM, IMNM, NAMS, and CLDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$39.12 -3.3%	$38.51	$21.71 ▼ $45.14	$3.07B	0.87	868,254 shs	424,938 shs
CLYM Climb Bio	$14.57 -3.3%	$13.82	$1.54 ▼ $18.33	$836.84M	0.08	1.22 million shs	840,720 shs
IMNM Immunome	$27.57 -4.5%	$24.20	$8.66 ▼ $30.06	$3.13B	2.08	1.22 million shs	783,498 shs
NAMS NewAmsterdam Pharma	$25.90 -3.3%	$30.33	$23.05 ▼ $42.21	$3.10B	0.1	1.13 million shs	1.04 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	0.00%	-3.12%	+1.64%	+24.47%	+73.10%
CLYM Climb Bio	0.00%	-15.68%	+19.72%	+32.94%	+536.24%
IMNM Immunome	0.00%	-3.33%	+19.45%	+26.29%	+177.09%
NAMS NewAmsterdam Pharma	0.00%	-7.07%	-9.00%	-23.10%	+5.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$39.12 -3.3%	$38.51	$21.71 ▼ $45.14	$3.07B	0.87	868,254 shs	424,938 shs
CLYM Climb Bio	$14.57 -3.3%	$13.82	$1.54 ▼ $18.33	$836.84M	0.08	1.22 million shs	840,720 shs
IMNM Immunome	$27.57 -4.5%	$24.20	$8.66 ▼ $30.06	$3.13B	2.08	1.22 million shs	783,498 shs
NAMS NewAmsterdam Pharma	$25.90 -3.3%	$30.33	$23.05 ▼ $42.21	$3.10B	0.1	1.13 million shs	1.04 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	0.00%	-3.12%	+1.64%	+24.47%	+73.10%
CLYM Climb Bio	0.00%	-15.68%	+19.72%	+32.94%	+536.24%
IMNM Immunome	0.00%	-3.33%	+19.45%	+26.29%	+177.09%
NAMS NewAmsterdam Pharma	0.00%	-7.07%	-9.00%	-23.10%	+5.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.85	Moderate Buy	$56.08	43.36% Upside
CLYM Climb Bio	3.00	Buy	$23.08	58.43% Upside
IMNM Immunome	2.85	Moderate Buy	$34.64	25.63% Upside
NAMS NewAmsterdam Pharma	2.92	Moderate Buy	$49.73	92.00% Upside

Current Analyst Ratings Breakdown

Latest CLYM, IMNM, NAMS, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $24.00
8/19/2026	CLYM Climb Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
8/12/2026	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$31.00 ➝ $35.00
8/12/2026	IMNM Immunome	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00
8/7/2026	CLDX Celldex Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $53.00
8/7/2026	CLYM Climb Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $25.00
8/6/2026	NAMS NewAmsterdam Pharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$51.00 ➝ $50.00
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Moderate Buy	$23.00
7/29/2026	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $72.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$1.54M	1,994.87	N/A	N/A	$9.10 per share	4.30
CLYM Climb Bio	N/A	N/A	N/A	N/A	$4.17 per share	N/A
IMNM Immunome	$6.94M	451.21	N/A	N/A	$4.62 per share	5.97
NAMS NewAmsterdam Pharma	$22.50M	137.60	N/A	N/A	$5.28 per share	4.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/5/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	11/4/2026 (Estimated)

Latest CLYM, IMNM, NAMS, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	11.82	11.82
CLYM Climb Bio	N/A	31.45	31.45
IMNM Immunome	N/A	15.08	15.08
NAMS NewAmsterdam Pharma	N/A	9.03	9.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
CLYM Climb Bio	69.76%
IMNM Immunome	44.58%
NAMS NewAmsterdam Pharma	89.89%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	5.20%
CLYM Climb Bio	2.60%
IMNM Immunome	7.21%
NAMS NewAmsterdam Pharma	12.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	78.53 million	74.45 million	Optionable
CLYM Climb Bio	9	57.44 million	55.94 million	N/A
IMNM Immunome	40	113.58 million	105.39 million	Optionable
NAMS NewAmsterdam Pharma	4	119.54 million	104.31 million	Optionable

CLYM, IMNM, NAMS, and CLDX Headlines

Recent News About These Companies

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

August 26, 2026 | globenewswire.com

NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 125,000 Shares

August 26, 2026 | insidertrades.com

NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 125,000 Shares of Stock

August 25, 2026 | marketbeat.com

Analysts Set NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Price Target at $49.33

August 23, 2026 | americanbankingnews.com

Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)

August 23, 2026 | theglobeandmail.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 18, 2026 | marketbeat.com

NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Bank of America Corp DE

August 17, 2026 | marketbeat.com

NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Handelsbanken Fonder AB

August 16, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Outlook for NAMS Earnings

August 10, 2026 | marketbeat.com

NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript

August 8, 2026 | seekingalpha.com

Piper Sandler Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

August 8, 2026 | theglobeandmail.com

BMO Capital Remains a Buy on NewAmsterdam Pharma Company (NAMS)

August 7, 2026 | theglobeandmail.com

Equities Analysts Offer Predictions for NAMS FY2027 Earnings

August 7, 2026 | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Price Target Cut to $50.00 by Analysts at Royal Bank Of Canada

August 6, 2026 | marketbeat.com

NewAmsterdam Pharma Company NV (NAMS) reports Q2 loss, lags revenue estimates

August 6, 2026 | msn.com

NewAmsterdam Pharma (NASDAQ:NAMS) Announces Quarterly Earnings Results

August 5, 2026 | marketbeat.com

NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day - Slideshow

August 5, 2026 | seekingalpha.com

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

August 5, 2026 | marketbeat.com

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

August 5, 2026 | zacks.com

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

August 5, 2026 | globenewswire.com

RBC Capital Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)

August 2, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM, IMNM, NAMS, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$39.12 -1.34 (-3.31%)

As of 08/28/2026 04:00 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Climb Bio NASDAQ:CLYM

$14.57 -0.49 (-3.25%)

As of 08/28/2026 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Immunome NASDAQ:IMNM

$27.57 -1.30 (-4.50%)

As of 08/28/2026 04:00 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

NewAmsterdam Pharma NASDAQ:NAMS

$25.90 -0.89 (-3.32%)

As of 08/28/2026 04:00 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLYM, IMNM, NAMS, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLYM, IMNM, NAMS, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLYM, IMNM, NAMS, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM, IMNM, NAMS, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

Climb Bio NASDAQ:CLYM

Immunome NASDAQ:IMNM

NewAmsterdam Pharma NASDAQ:NAMS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLYM, IMNM, NAMS, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLYM, IMNM, NAMS, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLYM, IMNM, NAMS, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM, IMNM, NAMS, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

Climb Bio NASDAQ:CLYM

Immunome NASDAQ:IMNM

NewAmsterdam Pharma NASDAQ:NAMS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools